Quince Therapeutics stock, biotechnology

Quince Therapeutics stock falls 3.83 percent on Nasdaq

Published on 09/24/2026 at 06:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Quince Therapeutics stock stood at USD 30.15 on September 23, 2026, with a market capitalization of USD 8,394,001. A September 28 event will spotlight LAM-001.

Quince Therapeutics stock, biotechnology, LAM-001, Nasdaq compliance, Nasdaq, Illustration mit AI erstellt.

Quince Therapeutics stock (ISIN US22053A3059) fell 3.83 percent to USD 30.15 on Nasdaq on September 23, 2026, down USD 1.20 from the previous close of USD 31.35. The move came as the biotechnology company prepared a September 28 virtual event on its LAM-001 pulmonary drug program, announced by GlobeNewswire on September 17, 2026.

Nasdaq equity issue sets a deadline

Quince reported stockholders' equity of negative USD 35.324 million as of June 30, 2026, compared with Nasdaq's required minimum of USD 10 million. The gap is USD 45.324 million, making balance-sheet repair more immediate than the share-price move alone suggests.

The Nasdaq notice gives Quince until October 15, 2026, to submit a compliance plan, according to StockTitan. Trading on the Nasdaq Global Select Market continued under QNCX, while the company evaluated a possible transfer to the Nasdaq Capital Market.

LAM-001 supplies the pipeline catalyst

The September 28 event will address pulmonary hypertension associated with interstitial lung disease and bronchiolitis obliterans syndrome after lung transplant. The company describes LAM-001 as a once-daily inhaled formulation of rapamycin in Phase 2 development, according to GlobeNewswire.

Quince anticipates data from the bronchiolitis obliterans syndrome program in the first quarter of 2027, while data from the Phase 2b pulmonary hypertension study are anticipated in the first quarter of 2028. Those dates give the stock a defined clinical timetable, but the Nasdaq equity requirement remains the nearer corporate checkpoint.

Stock trades inside a wide session range

Quince shares traded between USD 29.03 and USD 31.01 on September 23, 2026. The market capitalization was USD 8,394,001 as of September 24, 2026, while the USD 30.15 price sat USD 0.86 below the session high.

The combination of a 3.83 percent daily decline, the negative USD 35.324 million equity position and the September 28 clinical event leaves investors with two distinct variables: Nasdaq compliance and LAM-001 execution.